Acceder
  1. Inicio
  2. Perfil de angelpm1
  3. Contenidos recomendados por angelpm1

Contenidos recomendados por angelpm1

angelpm1 11/12/15 11:56
Ha respondido al tema Farmas USA
Buenos scripts!!! AMRN Hoy debería subir... todo unido a la noticia de ayer....
Ir a respuesta
angelpm1 10/12/15 13:15
Ha respondido al tema Farmas USA
Hola Framus. NVAX. ¿Se espera que digan algo relevante en la conferencia del 15 de Diciembre? Los datos de los trials ¿son a mediados / finales del año que viene? ¿No? Hasta esas fechas ¿como esperas que sea la evolución del precio de NVAX? ¿Laterales? Muchas gracias y saludos.
Ir a respuesta
angelpm1 04/12/15 10:50
Ha respondido al tema Farmas USA
AMRN Week 27/11 (4 días, no 5; 1 día festivo) –V– TRx:12,803 {vs14,892; -14.03%} Sec -12.49% NRx:5,154 {vs6,514;-20.88%}Sec 19.75% Ref:7,649 {vs8,378; -8.70%}Sec -7.77% V TRx Market Share: 16.48% vs 16.78% V NRx Market Share: 18.38% vs 18.64% V Ref Market Share: 15.41% vs 15.57% L: TRx: 3,675{vs 4,020; -8.58%} NRx: 1,238{vs 1,322; -6.35%} GenL: TRx: 61,211 {vs 69,861; -12.38%} NRx: 21,653 {vs 27,113; -20.14%}
Ir a respuesta
angelpm1 01/12/15 15:26
Ha respondido al tema Farmas USA
AMRN Plasma α-Linolenic & Omega 3 Fatty Acids Associated w/ Lower Risk Acute Myocardial Infarction Chinese Adults http://jn.nutrition.org/content/early/2015/11/25/jn.115.220418.abstract Scientific Basis for a Public Health Recommendation for EPA/DHA http://www.crn-i.ch/2015symposium/6_Rice.pdf
Ir a respuesta
angelpm1 01/12/15 15:23
Ha respondido al tema Farmas USA
ARNA Eisai and Arena Announce Completion of Enrollment in BELVIQ® (lorcaserin HCI) CAMELLIA-TIMI 61 Study Arena Pharmaceuticals' NDA on Weight-Loss Treatment BELVIQ XR Accepted by FDA
Ir a respuesta
angelpm1 01/12/15 13:01
Ha respondido al tema Farmas USA
THLD Pero menos perdidas que lo reportado con anterioridad. As per the set of brokerage research firms, which were surveyed by Zacks Research, Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) is likely to report earnings per share of $-0.07 for its most recent fiscal quarter. The company’s quarterly results are due to release on or around 2016-03-01. Since the data gathered by Zacks and Thomson Reuters does not come from the same set of brokers, therefore, there is likelihood that the Zacks estimates are slightly different from that of First Call forecasts. Meanwhile, both institutional and retail investors will be closely following the revisions in the forecasts up ahead of the earnings release date. During the financial period ended on 2015-09-30, the Threshold Pharmaceuticals, Inc. reported earnings at $-0.09 per share. The number so reported led to a surprise factor of 30.77% or below $0.04 from what the analysts had anticipated just before the release of the earnings.
Ir a respuesta
angelpm1 01/12/15 12:54
Ha respondido al tema Farmas USA
THLD http://www.investornewswire.com/analyst-views/threshold-pharmaceuticals-inc-nasdaqthld-earnings-update/68030/ Earnings update: $-0.07 en vez de $-0.09
Ir a respuesta
angelpm1 01/12/15 12:07
Ha respondido al tema Farmas USA
THLD Framus.. has hecho bien... hay que estar confortable con las inversiones... ahora con media carga tienes menos incertidumbre... a ver si hay ese rally hasta los 5 USD!!!! ¿Has leído esto? http://www.insidermonkey.com/blog/hedge-funds-are-crazy-about-threshold-pharmaceuticals-inc-thld-391748/
Ir a respuesta